國立虎尾科技大學 |

Reviews on New Drug Targets in Age-Related Disorders

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Reviews on New Drug Targets in Age-Related Disorders/ edited by Paul C. Guest.
其他作者:	Guest, Paul C.
面頁冊數:	VIII, 340 p. 52 illus., 40 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Systems Biology. -
電子資源:	https://doi.org/10.1007/978-3-030-42667-5
ISBN:	9783030426675

Reviews on New Drug Targets in Age-Related Disorders
Reviews on New Drug Targets in Age-Related Disorders[electronic resource] /edited by Paul C. Guest. - 1st ed. 2020. - VIII, 340 p. 52 illus., 40 illus. in color.online resource. - Proteomics, Metabolomics, Interactomics and Systems Biology,12602730-6216 ;. - Proteomics, Metabolomics, Interactomics and Systems Biology,1055.

Ch-01 Targeting ROS-mediated Crosstalk between Autophagy and Apoptosis in Cancer -- Ch-02 Micronutrients that Affect Immunosenescence -- Ch-03 Bioactive Lipids in Age-Related Disorders -- Ch-04 Effect of Short Chain Fatty Acids on Age-Related Disorders -- Ch-05 The Effects of Parabiosis on Aging and Age-related Diseases -- Ch-06 Skeletal Muscle Aging Atrophy: Assessment and Exercise-Based Treatment -- Ch-07 Polyphenols as an Effective Therapeutic Intervention Against Cognitive Decline during Normal and Pathological Brain Aging -- Ch-08 Early Diagnosis and Targeted Treatment Strategy for Improved Therapeutic Outcomes in Alzheimer’s Disease -- Ch-09 Resetting the Aging Clock: Implications for Managing Age-Related Diseases -- Ch-10 The Challenge of Antidepressant Therapeutics in Alzheimer's Disease -- Ch-11 Anxiolytic Terpenoids and Aromatherapy for Anxiety and Depression -- Ch-12 The Role of Nutrition in Attenuating Age-Related Skeletal Muscle Atrophy -- Ch-13 The Use of Metformin to Increase the Human Healthspan.

Aging is an inevitable part of life and is becoming a worldwide social, economic and health problem. This is mainly due to the fact that the increasing proportion of individuals in the advanced age category have a higher probability of developing age-related disorders, such as type II diabetes mellitus, cardiovascular disorders, sarcopenia, and neurodegenerative conditions. New therapeutic approaches are still needed to decrease or slow the effects of such diseases. Advances in -omic technologies, such as genomics, transcriptomics, proteomics and metabolomics, have significantly advanced our understanding of disease in multiple medical areas, as the analysis of multiple molecular networks has simultaneously provided a more integrated view of disease pathways. It is hoped that emerging hits from these analyses might be prioritized for further screening as potential novel drug targets for increasing the human healthspan in line with the lifespan. In turn, this will lead to new therapeutic strategies as well as drug development projects by the pharmaceutical industry. This book presents a series of reviews describing studies that have resulted in identification of new potential drug targets for age-related disorders. Much of this information has come from -omic comparisons of healthy and disease states or from testing the effects of new therapeutic approaches. Authored by experts from around the globe, each chapter is presented in the context of specific chronic diseases or therapeutic strategies. This book is designed for researchers in the areas of aging and chronic disease, as well as clinical scientists, physicians and stakeholders in major drug companies. .

ISBN: 9783030426675

Standard No.: 10.1007/978-3-030-42667-5doiSubjects--Topical Terms:

683756
Systems Biology.

LC Class. No.: QD431-431.7

Dewey Class. No.: 572.6

Reviews on New Drug Targets in Age-Related Disorders
LDR:04185nam a22004095i 4500 001 1027991
003 DE-He213
005 20200629192657.0
007 cr nn 008mamaa
008 210318s2020 gw | s |||| 0|eng d
020 $a 9783030426675 $9 978-3-030-42667-5
024 7 $a 10.1007/978-3-030-42667-5 $2 doi
035 $a 978-3-030-42667-5
050 4 $a QD431-431.7
072 7 $a PSBC $2 bicssc
072 7 $a SCI007000 $2 bisacsh
072 7 $a PSB $2 thema
082 0 4 $a 572.6 $2 23
245 1 0 $a Reviews on New Drug Targets in Age-Related Disorders $h [electronic resource] / $c edited by Paul C. Guest.
250 $a 1st ed. 2020.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a VIII, 340 p. 52 illus., 40 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Proteomics, Metabolomics, Interactomics and Systems Biology, $x 2730-6216 ; $v 1260
505 0 $a Ch-01 Targeting ROS-mediated Crosstalk between Autophagy and Apoptosis in Cancer -- Ch-02 Micronutrients that Affect Immunosenescence -- Ch-03 Bioactive Lipids in Age-Related Disorders -- Ch-04 Effect of Short Chain Fatty Acids on Age-Related Disorders -- Ch-05 The Effects of Parabiosis on Aging and Age-related Diseases -- Ch-06 Skeletal Muscle Aging Atrophy: Assessment and Exercise-Based Treatment -- Ch-07 Polyphenols as an Effective Therapeutic Intervention Against Cognitive Decline during Normal and Pathological Brain Aging -- Ch-08 Early Diagnosis and Targeted Treatment Strategy for Improved Therapeutic Outcomes in Alzheimer’s Disease -- Ch-09 Resetting the Aging Clock: Implications for Managing Age-Related Diseases -- Ch-10 The Challenge of Antidepressant Therapeutics in Alzheimer's Disease -- Ch-11 Anxiolytic Terpenoids and Aromatherapy for Anxiety and Depression -- Ch-12 The Role of Nutrition in Attenuating Age-Related Skeletal Muscle Atrophy -- Ch-13 The Use of Metformin to Increase the Human Healthspan.
520 $a Aging is an inevitable part of life and is becoming a worldwide social, economic and health problem. This is mainly due to the fact that the increasing proportion of individuals in the advanced age category have a higher probability of developing age-related disorders, such as type II diabetes mellitus, cardiovascular disorders, sarcopenia, and neurodegenerative conditions. New therapeutic approaches are still needed to decrease or slow the effects of such diseases. Advances in -omic technologies, such as genomics, transcriptomics, proteomics and metabolomics, have significantly advanced our understanding of disease in multiple medical areas, as the analysis of multiple molecular networks has simultaneously provided a more integrated view of disease pathways. It is hoped that emerging hits from these analyses might be prioritized for further screening as potential novel drug targets for increasing the human healthspan in line with the lifespan. In turn, this will lead to new therapeutic strategies as well as drug development projects by the pharmaceutical industry. This book presents a series of reviews describing studies that have resulted in identification of new potential drug targets for age-related disorders. Much of this information has come from -omic comparisons of healthy and disease states or from testing the effects of new therapeutic approaches. Authored by experts from around the globe, each chapter is presented in the context of specific chronic diseases or therapeutic strategies. This book is designed for researchers in the areas of aging and chronic disease, as well as clinical scientists, physicians and stakeholders in major drug companies. .
650 2 4 $a Systems Biology. $3 683756
650 2 4 $a Geriatrics/Gerontology. $3 673757
650 2 4 $a Pharmaceutical Sciences/Technology. $3 768561
650 2 4 $a Metabolomics. $3 882386
650 0 $a Systems biology. $3 600045
650 0 $a Geriatrics. $3 645067
650 0 $a Pharmaceutical technology. $3 557391
650 0 $a Metabolism. $3 581368
650 0 $a Proteomics. $3 581930
700 1 $a Guest, Paul C. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1139505
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030426668
776 0 8 $i Printed edition: $z 9783030426682
776 0 8 $i Printed edition: $z 9783030426699
830 0 $a Proteomics, Metabolomics, Interactomics and Systems Biology, $x 2730-6216 ; $v 1055 $3 1285713
856 4 0 $u https://doi.org/10.1007/978-3-030-42667-5
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)